Review of Testing and Use of Adjuvant Trastuzumab across a Cancer Network - Are We Treating the Right Patients?

被引：17

作者：

Coulson, S. G. ^{[1
]}

Kumar, V. S. ^{[1
]}

Manifold, I. M. ^{[1
]}

Hatton, M. Q. ^{[1
]}

Ramakrishnan, S. ^{[1
]}

Dunn, K. S. ^{[1
]}

Purohit, O. P. ^{[1
]}

Bridgewater, C. ^{[1
]}

Coleman, R. E. ^{[1
]}

机构：

[1] Weston Pk Hosp, Acad Unit Clin Oncol, Sheffield S10 2SJ, S Yorkshire, England

来源：

CLINICAL ONCOLOGY | 2010年 / 22卷 / 04期

关键词：

Adjuvant therapy; breast cancer; HER2; trastuzumab; METASTATIC BREAST-CANCER; 1ST-LINE TREATMENT; CHEMOTHERAPY; DOCETAXEL; EFFICACY; SAFETY; PLUS;

D O I：

10.1016/j.clon.2010.02.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This review of practice assessed all early breast cancer patients diagnosed over 12 months to determine the frequency of human epidermal growth factor receptor 2 (HER2) positivity and trastuzumab use. The frequency of HER2 positivity in routine practice (185/1319; 14%) was less than expected. A significant proportion of patients (56/185; 30%) did not receive trastuzumab, largely clue to concerns about chemotherapy tolerability. (C) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

引用

页码：289 / 293

页数：5

共 19 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2]

[Anonymous], 2006, Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer

[3] Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer [J].

Curigliano, Giuseppe ;

Viale, Giuseppe ;

Bagnardi, Vincenzo ;

Fumagalli, Luca ;

Locatelli, Marzia ;

Rotmensz, Nicole ;

Ghisini, Raffaella ;

Colleoni, Marco ;

Munzone, Elisabetta ;

Veronesi, Paolo ;

Zurrida, Stefano ;

Nole, Franco ;

Goldhirsch, Aron .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5693-5699

[4] THE NOTTINGHAM PROGNOSTIC INDEX IN PRIMARY BREAST-CANCER [J].

GALEA, MH ;

BLAMEY, RW ;

ELSTON, CE ;

ELLIS, IO .

BREAST CANCER RESEARCH AND TREATMENT, 1992, 22 (03) :207-219

[5] High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2-Positive, Node-Negative Tumors 1 cm or Smaller [J].

Gonzalez-Angulo, Ana M. ;

Litton, Jennifer K. ;

Broglio, Kristine R. ;

Meric-Bernstam, Funda ;

Rakkhit, Ronjay ;

Cardoso, Fatima ;

Peintinger, Florentia ;

Hanrahan, Emer O. ;

Sahin, Aysegul ;

Guray, Merih ;

Larsimont, Denis ;

Feoli, Francesco ;

Stranzl, Heidi ;

Buchholz, Thomas A. ;

Valero, Vicente ;

Theriault, Richard ;

Piccart-Gebhart, Martine ;

Ravdin, Peter M. ;

Berry, Donald A. ;

Hortobagyi, Gabriel N. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5700-5706

[6] Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer [J].

Joensuu, H ;

Kellokumpu-Lehtinen, P ;

Bono, P ;

Alanko, T ;

Kataja, V ;

Asola, R ;

Utriainen, T ;

Kokko, R ;

Hemminki, A ;

Tarkkanen, M ;

Turpeenniemi-Hujanen, T ;

Jyrkkiö, S ;

Flander, M ;

Helle, L ;

Ingalsuo, S ;

Johansson, K ;

Jääskeläinen, A ;

Pajunen, M ;

Rauhala, M ;

Kaleva-Kerola, J ;

Salminen, T ;

Leinonen, M ;

Elomaa, I ;

Isola, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) :809-820

[7] Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study [J].

Kaufman, Bella ;

Mackey, John R. ;

Clemens, Michael R. ;

Bapsy, Poonamalle P. ;

Vaid, Ashok ;

Wardley, Andrew ;

Tjulandin, Sergei ;

Jahn, Michaela ;

Lehle, Michaela ;

Feyereislova, Andrea ;

Revil, Cedric ;

Jones, Alison .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5529-5537

[8] Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group [J].

Marty, M ;

Cognetti, F ;

Maraninchi, D ;

Snyder, R ;

Mauriac, L ;

Tubiana-Hulin, M ;

Chan, S ;

Grimes, D ;

Antón, A ;

Lluch, A ;

Kennedy, J ;

O'Byrne, K ;

Conte, P ;

Green, M ;

Ward, C ;

Mayne, K ;

Extra, JM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) :4265-4274

[9] HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors [J].

Nielsen, Dorte Lisbet ;

Andersson, Michael ;

Kamby, Claus .

CANCER TREATMENT REVIEWS, 2009, 35 (02) :121-136

[10]

*OFF NAT STAT, 2009, SER MBI, V37

← 1 2 →